ArticleAnnals of surgical oncology2026
Association Between Postoperative Skeletal Muscle Loss and Disease-Free Survival in Node-Negative NSCLC ≤ 4 cm Without Adjuvant Therapy: A 5-Years Trend Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic role of preoperative skeletal muscle mass index in surgical lung cancer patients: a systematic review with meta-analysis.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in treatment, approximately 20% of patients with early stage non-small cell lung cancer (NSCLC) will experience recurrence. Sarcopenia has emerged as a potential prognostic factor in lung cancer. We hypothesize that rate of skeletal muscle volume loss after lung resection is associated with disease-free survival (DFS). PATIENTS AND
methodsA retrospective analysis was conducted on 316 patients with node-negative NSCLC (≤ 4 cm) who underwent lung resection between 2010 and 2021. Those receiving neoadjuvant or adjuvant therapy or experiencing recurrence within 12 months of surgery were excluded. Skeletal muscle index (SMI) was measured preoperatively and annually for up to 5 years. Locally estimated scatterplot smoothing (LOESS) regression was used to visualize trends in SMI over time, and cut-point analysis identified the optimal slope of SMI change associated with DFS. The association between SMI slope and DFS was further evaluated using multivariable Cox proportional hazards models, adjusting for relevant demographic and clinical covariates.
resultsLOESS analysis revealed an initial plateau in SMI during the first postoperative year across all patients, followed by a marked decline in patients that recurred. The greatest loss in SMI occurred in the year immediately preceding radiographic identification of recurrence. In Cox proportional hazards analysis, patients with an SMI loss greater than 13.5 units/year had worse DFS (hazard ratio [HR] 11.97, 95% confidence interval [CI] 5.54-25.87, p < 0.001).
conclusionsRate of skeletal muscle loss after lung resection may be an early marker for NSCLC recurrence, underscoring the need for longitudinal SMI monitoring as part of routine postoperative surveillance.
Indexed as
Identifiers
40946122What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.